Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma

References

• European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: PubliComm Srl; 2014.
   Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
   PubMed Web of Science ®Google Scholar
• Kobelt-Nguyen G, Gerdtham U-G, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998;7:95–104.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Mocan MC, Katsanos A, et al. Latanoprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Pharmacother. 2013;14:1815–1827.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AGP, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117–1122.
   PubMed Web of Science ®Google Scholar
• Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722–732.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–719.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460–467.
   PubMed Web of Science ®Google Scholar
• Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82:935–939.
   PubMed Web of Science ®Google Scholar
• Petrilla AA, Benner JS, Battleman DS, et al. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract. 2005;59:1441–1451.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407.
   PubMed Web of Science ®Google Scholar
• Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging. 2015;32:569–581.
   PubMed Web of Science ®Google Scholar
• Olthoff CMG, Schouten JSAG, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953–961.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Maskaleris G, Gratsonidis S, et al. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14:752–756.
   PubMed Web of Science ®Google Scholar
• Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005;16:114–121.
   PubMedGoogle Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132–135.
   PubMedGoogle Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.
   PubMedGoogle Scholar
• Konstas AGP, Haidich A-B, Rossetti L, et al. Prostaglandin-timolol fixed combinations efficacy: myth or reality? Editorial. Eur J Ophthalmol. 2012;22:1–4.
   PubMed Web of Science ®Google Scholar
• Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure–lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737–1747.
   PubMed Web of Science ®Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30–S36.
   PubMedGoogle Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–S68.
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–868.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Quaranta L, Katsanos A, et al. Fixed combination therapies in glaucoma. In: Shaarawy T, Hitchings R, Sherwood M, et al., editors. Glaucoma. New York: Elsevier; 2015. p. 583–592.
   Google Scholar
• Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711–716.
   PubMed Web of Science ®Google Scholar
• Boboridis KG, Konstas AGP, Toumanidou V, et al. A 6-month, observational trial investigating with electronic monitoring the level of adherence and ocular surface health with latanoprost/timolol fixed versus latanoprost and timolol unfixed therapy in glaucoma. Invest Ophthalmol Vis Sci. 2012;53:E–Abstract5097.
   Google Scholar
• Konstas AGP, Quaranta L, Realini T. Overview of the [corrected] travoprost /timolol BAK-free fixed combination. Expert Opin Pharmacother. 2012;13:757–766.
   PubMed Web of Science ®Google Scholar
• Tabet R, Stewart WC, Feldman R, et al. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008;53:S85–S92.
   PubMed Web of Science ®Google Scholar
• Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004;5:909–921.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Voudouragkaki IC, Boboridis KG, et al. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014;31:592–603.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Shimazaki A, Tonouchi A, et al. Benefits of tafluprost and timolol fixed-dose combination for the treatment of glaucoma are confirmed by studies on experimental animal models. J Ocul Pharmacol Ther. 2015;31:518–524.
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22:5–18.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixedcombinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:382–389.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898–902.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Mikropoulos D, Haidich A-B, et al. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009;93:481–485.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Holló G, Mikropoulos DG, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94:209–213.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Nakos E, Tersis I, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002;133:753–757.
   PubMed Web of Science ®Google Scholar
• Takmaz T, Aşik S, Kürkçüoğlu P, et al. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur J Ophthalmol. 2008;18:60–65.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Tsironi S, Vakalis AN, et al. Intraocular pressure control over 24-hours using travoprost and timolol fixed combination, administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol. 2009;87:71–76.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Pikilidou MI, Tsironi S, et al. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr Eye Res. 2009;34:369–377.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos DG, Embeslidis TA, et al. 24-h intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye. 2010;24:1606–1613.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334.
   PubMed Web of Science ®Google Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4:59–64.
   Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther. 2011;28:501–510.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618–621.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1–9.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br J Ophthalmol. 2002;86:418–423.
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
   PubMed Web of Science ®Google Scholar
• Broadway D, Hitchings R, Grierson I. Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery. J Glaucoma. 1995;4:136.
   PubMedGoogle Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–735.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014;15:2255–2262.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Traverso CE, Lorenz K, et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31:1228–1246.
   PubMed Web of Science ®Google Scholar
• Holló G, Hommer A, Antón López A, et al. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30:468–475.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Drug Saf. 2015;14:609–617.
   PubMed Web of Science ®Google Scholar
• Holló G, Vuorinen J, Tuominen J, et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932–944.
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Ikäheimo K, Mannermaa E, et al. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies. Clin Pharmacokinet. 2016;55:485–494.
   PubMed Web of Science ®Google Scholar
• Santen O. Taptiqom 15 micrograms/ml+5 mg/ml eye drops, solution in single-dose container: summary of product characteristics. 2014. Available from: http://www.mhra.gov.uk/spc-pil/.
   Google Scholar
• Konstas AGP, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1510–1515.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–336.
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Agnifili L, Fasanella V, et al. Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Invest Ophthalmol Vis Sci. 2015;56:2050–2058.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Agnifili L, Mastropasqua R, et al. In vivo laser scanning confocal microscopy of the ocular surface in glaucoma. Microsc Microanal. 2014;20:879–894.
   PubMed Web of Science ®Google Scholar
• Mastropasqua L, Agnifili L, Fasanella V, et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013;91:e397–e405.
   PubMed Web of Science ®Google Scholar
• Agnifili L, Fasanella V, Costagliola C, et al. In vivo confocal microscopy of meibomian glands in glaucoma. Br J Ophthalmol. 2013;97:343–349.
   PubMed Web of Science ®Google Scholar
• Papadia M, Bagnis A, Scotto R, et al. Tafluprost for glaucoma. Expert Opin Pharmacother. 2011;12:2393–2401.
   PubMedGoogle Scholar
• Pantcheva MB, Seibold LK, Awadallah NS, et al. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011;28:707–715.
   PubMed Web of Science ®Google Scholar
• Chabi A, Varma R, Tsai JC, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012;153:1187–1196.
   PubMed Web of Science ®Google Scholar
• Erb C, Lanzl I, Seidova S-F, et al. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011;28:575–585.
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol. 1993;9:373–384.
   PubMedGoogle Scholar
• Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers. Ann Pharmacother. 1996;30:43–54.
   PubMed Web of Science ®Google Scholar
• Radcliffe NM. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014;12:2541–2549.
   Google Scholar
• Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140:242–250.
   PubMed Web of Science ®Google Scholar
• Amyot M, Blondeau P. Timolol maleate. Pharmacology and review of the literature. Can J Ophthalmol. 1979;14:208–214. French.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12–19.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tafluprost/timolol: a review in open-angle glaucoma or ocular hypertension. Drugs. 2015;75:1807–1813.
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279–1283.
   PubMed Web of Science ®Google Scholar
• Egorov E, Ropo A; Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol. 2009;19:214–222.
   PubMed Web of Science ®Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45–52.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Olander KW, Kim EE, et al.; United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128:165–172.
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson L-I; European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70–76.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:183–190.
   PubMed Web of Science ®Google Scholar
• Palmberg P, Kim EE, Kwok KK, et al. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010;20:708–718.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1–7.
   PubMed Web of Science ®Google Scholar
• Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14:392–399.
   PubMed Web of Science ®Google Scholar
• Teus MA, Miglior S, Laganovska G, et al. Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:629–636.
   PubMedGoogle Scholar
• Kitazawa Y, Smith P, Sasaki N, et al. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye. 2011;25:1161–1169.
   PubMed Web of Science ®Google Scholar
• Hommer A; Ganfort® Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53–62.
   PubMed Web of Science ®Google Scholar
• Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17:211–216.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Gross RL, Sall KN, et al. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized, parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19:424–426.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Gil Pina R, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014;98:926–931.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Holló G, Teus MA, et al. Exfoliation syndrome and glaucoma. In: Samples JR, Schacknow PN, editors. Clinical glaucoma care. New York (NY): Springer; 2014. p. 345–360.
   Google Scholar
• Holló G, Ropo A. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma. Curr Med Res Opin. 2015;31:13–16.
   PubMed Web of Science ®Google Scholar